机构：[1]Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.[2]Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.[3]Perelman School of Medicine, Philadelphia, Pennsylvania, 19104, United States.[4]Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.[5]Department of Neurosurgery, Xiangya Hospital, Central South University, Hunan, 410011, China.[6]Department of Surgery, Hospital of the University of Pennsylvania, Silverstein, Philadelphia, Pennsylvania, 19104, United States.[7]Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China.[8]Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.[9]Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.[10]Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, 02120, United States.[11]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院
Due to its rarity, current literature assessing prognostic factors and survival outcomes of hemangioblastoma is limited. Patients with histologically confirmed hemangioblastoma were identified from the US National Cancer Data Base. 1488 patients met inclusion criteria. 644 patients underwent gross total resection (GTR), 220 subtotal resection (STR)/biopsy, 60 stereotactic radiosurgery (SRS), 15 external beam radiotherapy (EBRT), 51 surgery followed by radiotherapy (SR + RT) and 498 no treatment. Independent predictors of shorter OS included age >= 40 (HR, 3.897; 95% CI, 2.341-6.487; p < 0.001), Charlson-Deyo score >= 1(HR, 1.756; 95% CI, 1.213-2.544; p = 0.003), tumor location in the brainstem (HR, 1.955; 95% CI, 1.129-3. 384; p = 0.017) compared to cerebellum, no treatment (HR, 2530; 95% CI, 1.533-4.177; p < 0.001) and receipt of EBRT (HR, 2.860; 95% CI, 1.073-7.618; p = 0.036) compared to STR/biopsy. GTR was associated with longer OS (HR 0.617; 95% CI, 0.391-0.974; p = 0.038), while SRS had comparable OS to STR/biopsy. The overall trend of OS by treatment modality was consistent after matching to age-and sex-matched US population data. In patients younger than 40 years, treatment was not a significant predictor of OS. In conclusion, GTR remained the optimal treatment for hemangioblastoma. SRS may perform similarly to surgery alone. Treatment was not a significant predictor of survival in younger patients.
基金：
ShenghuaYuying Project of Central South University [81472594, 81770781]; National Science Foundation of ChinaNational Natural Science Foundation of China [81472594, 81770781]
第一作者机构：[1]Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.[2]Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
推荐引用方式(GB/T 7714)：
Huang Yuqian,Chan Lilian,Bai Harrison X.,et al.Assessment of care pattern and outcome in hemangioblastoma[J].SCIENTIFIC REPORTS.2018,8(1):-.doi:10.1038/s41598-018-29047-9.
APA：
Huang, Yuqian,Chan, Lilian,Bai, Harrison X.,Li, Xuejun,Zhang, Zishu...&Yang, Li.(2018).Assessment of care pattern and outcome in hemangioblastoma.SCIENTIFIC REPORTS,8,(1)
MLA：
Huang, Yuqian,et al."Assessment of care pattern and outcome in hemangioblastoma".SCIENTIFIC REPORTS 8..1(2018):-
